Akebia’s shares fell 21.6% following the quarter as investors reacted negatively to an unexpectedly cautious outlook and indicators of deceleration in key metrics despite some progress in product launch and clinical data.

• Vafseo net product revenue reached nearly $16 million in Q1, the highest quarter to date, reflecting initial growth from expanded prescribing and observed dosing protocols.
• Clinical evidence continues to build with published INNOVATE trial data showing reduced hospitalization risks and costs for Vafseo-treated patients versus ESA comparators.
• The company emphasized ongoing trials VOCAL and VOICE, with data expected by year-end 2026 and early 2027, respectively, to validate Vafseo’s clinical profile and support future adoption.
• R&D pipeline advances include Phase II studies for praliciguat in FSGS and Abribafisp targeting complement-mediated kidney diseases, but these remain early-stage with no imminent commercial impact.
• Despite these developments, investor disappointment likely stemmed from tempered forward guidance or lack of clearer acceleration in revenue growth and further margin improvement.